Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer

Radiotherapy (RT) is an integral component of nasopharyngeal cancer (NPC) management. Advanced RT techniques such as intensity-modulated radiotherapy (IMRT) have improved the anatomical precision of local treatment for primary NPC.[1] Despite this, around 20 –30 % of patients develop local recurrence and/or distant metastases.[2] Additionally, up to 50 % of patients in remission experience RT-induced late toxicities.[3] Current radiation dose protocols are uniformly standardized at 66–70 Gy for gross disease and 54–60 Gy for elective nodal regions, despite substantial heterogeneity in treatment response.

Source: Radiotherapy and Oncology - April 16, 2024 Category: Radiology Authors: Chi Leung Chiang, Kenneth Sik Kwan Chan, Huaping Li, Wai Tong Ng, James Chung Hang Chow, Horace Cheuk Wai Choi, Ka On Lam, Victor Ho Fun Lee, Roger Kai Cheong Ngan, Anne Wing Mui Lee, Steven A Eschrich, Javier F Torres-Roca, Jason Wing Hon Wong Tags: Original Article Source Type: research